CAMP4 Therapeutics Corporation
CAMP · NASDAQ
12/31/2024 | 12/31/2023 | 2/28/2023 | 2/28/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.01 | -3.85 | -0.29 |
| FCF Yield | -45.18% | -34.49% | -11.00% | -4.63% |
| EV / EBITDA | -0.90 | -2.06 | -7.17 | 66.21 |
| Quality | ||||
| ROIC | -73.94% | -103.35% | -46.41% | -5.03% |
| Gross Margin | 100.00% | 100.00% | 0.00% | 41.20% |
| Cash Conversion Ratio | 0.88 | 0.90 | 0.87 | 0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -89.42% | -100.00% | -6.86% |
| Free Cash Flow Growth | -2.61% | -5.32% | -143.02% | -201.67% |
| Safety | ||||
| Net Debt / EBITDA | 1.08 | 0.53 | 1.60 | 15.76 |
| Interest Coverage | 0.00 | 0.00 | -7.19 | -1.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 8.62 |
| Cash Conversion Cycle | 60.46 | 460.94 | 0.00 | 50.04 |